Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 208 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Papillomavirus (HPV) Infection Clear all
Completed Not applicable Interventional Accepts healthy volunteers

PREVENT Pilot HPV - Related Cancers Trial

NCT06738355
View directory record Official record
Conditions
HPV Vaccination, Uptake Vaccination, Series Completion
Interventions
PREVENT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of HPV Infection in Men: The HIM Study

NCT00786760
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Cohort: 3000 men examined every 6 months for 4 years., Pilot study: 150 men examined every 6 months for 4 years.
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
1,431 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women

NCT01366742
View directory record Official record
Conditions
Human Papillomavirus, CIN 2, CIN 3
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 22 Years · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1987 – 2016
U.S. locations
2
States / cities
San Francisco, California • San Leandro, California
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

NCT00695422
View directory record Official record
Conditions
Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
Interventions
polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy
Genetic · Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational Results available

Anal Human Papillomavirus in Inflammatory Bowel Disease Study

NCT01364896
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
Interventions
Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational

New Strategies to Assess Anal Cancer Risk In Women

NCT02873741
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV)
Interventions
Perianal and Digital Anorectal Exam, Cervical Swabs, Anal Swabs, High Resolution Anoscopy (HRA)
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

NCT03603808
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions
Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
Device · Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults

NCT00120848
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
HPV 16/18 VLP AS04
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 30 Years · Female only
Enrollment
776 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
17
States / cities
San Francisco, California • Augusta, Georgia • Bardstown, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE Study

NCT04660331
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Communication Intervention, Communication Skills Training, Healthcare Activity, Survey Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 13, 2026, 5:38 PM EDT
Recruiting Phase 3 Interventional

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918
View directory record Official record
Conditions
Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
Interventions
Cantharidin
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Saint Augustine, Florida • Plainfield, Indiana • Boardman, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers

NCT02355262
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Health Status Unknown, Human Papillomavirus Infection, Malignant Neoplasm
Interventions
Informational Intervention
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational

The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women

NCT00006444
View directory record Official record
Conditions
HIV Infections, Papilloma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
49
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 13, 2026, 5:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care

NCT06256718
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Educational Intervention
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Testing the Use of Prompts to Increase Adolescent Immunization Rates

NCT01984125
View directory record Official record
Conditions
Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis, Influenza
Interventions
Point-of-Care Prompt
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 18 Years
Enrollment
7,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03677960
View directory record Official record
Conditions
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasm
Interventions
Topical ABI-1968 cream
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
27 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia

NCT00303823
View directory record Official record
Conditions
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 1, Human Papilloma Virus Infection
Interventions
placebo, defined green tea catechin extract, laboratory biomarker analysis
Drug · Dietary Supplement · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 13, 2026, 5:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results

NCT01384370
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Not listed
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Lake Success, New York • Burlington, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Oct 13, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

NCT02890368
View directory record Official record
Conditions
Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma
Interventions
TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, TTI-621 + T-Vec, TTI-621 + radiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Duarte, California • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

NCT01084083
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin
Biological · Radiation · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

NCT04247282
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Neoplasms
Interventions
M7824, N803, TriAd vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 13, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

NCT07209189
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer, Laryngeal Cancer, Sinonasal Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, Skull Base Tumors, HPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions
Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 13, 2026, 5:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intralesional HPV Vaccine for Condylomata

NCT05087849
View directory record Official record
Conditions
Human Papilloma Virus, Warts, Warts, Genital, Condyloma, Condylomata Acuminata
Interventions
nonavalent human papillomavirus vaccine
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 13, 2026, 5:38 PM EDT
Not yet recruiting Not applicable Interventional

HPV Detection Using Self-Collected Menstrual Blood

NCT07733557
View directory record Official record
Conditions
Human Papillomavirus (HPV) Infection
Interventions
Endometrics Menstrual Blood Collection Kit
Device
Lead sponsor
Samantha Batman
Other
Eligibility
21 Years to 49 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 13, 2026, 5:38 PM EDT